• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Dementias Invite Scientists to Apply for FTD Grant Award Program

Posted on: Tuesday, 3 June 2008, 12:00 CDT

The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Dementias (AFTD) invite scientists from the biotechnology industry and academia worldwide to apply for research grants through the Frontotemporal Dementia Drug Discovery Program. The goal of the program is to catalyze and fund the discovery and development of effective therapies for frontotemporal dementia (FTD).

Applications may be submitted by non-profit academic institutions and for-profit public and private biotechnology companies. Funds may be used for high-throughput screening of novel compounds; advancing the development of lead compounds through pre-clinical in-vitro and in-vivo evaluation including pharmacology, toxicology, pharmacokinetics, formulation chemistry; and the conduct of pre-clinical proof of concept studies. Programs requesting funds to support the development and testing of targeted gene delivery strategies and biomarkers to accelerate early diagnosis will also be accepted. Requests for basic research funding will not be accepted.

Applications are available at www.alzdiscovery.org. The application submission deadline date is September 22, 2008.

Applications will be reviewed by an independent Scientific Review Committee convened by ADDF/AFTD and comprised of leading experts in the neurodegenerative disease drug discovery and development research field and biotechnology investment community. Selections will be made by January 15, 2009 and funding will be awarded on April 15.

About the Alzheimer's Drug Discovery Foundation (ADDF)

The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Estee Lauder family in 1998. Our sole mission is to accelerate drug discovery research to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging through venture philanthropy. To date, ADDF and ISOA have awarded $33 million for over 240 research programs and conferences worldwide. For more information about the ADDF, visit www.alzdiscovery.org.

About the Association for Frontotemporal Dementia

The Association for Frontotemporal Dementias (AFTD) is a nationwide non-profit organization whose mission is to promote and fund research into finding the cause and cure for the frontotemporal dementias; to provide information, education, and support to persons diagnosed with frontotemporal dementias (FTD) and their families and caregivers; and to educate physicians and allied health professionals about FTD. In addition to providing funding for this drug discovery program, AFTD continues to fund basic and clinical research that is essential to improving our understanding of this relatively rare, but significant disease. For more information about AFTD, visit www.ftd-picks.org.

 ADDF Contact: Filomena Machleder Partnership Relations Manager (212)901-8004 fmhachleder@alzdiscovery.org  ATFD Contact: Susan L-J Dickinson Executive Director (267) 514-7221 sdickinson@ftd-picks.org

SOURCE: Alzheimer's Drug Discovery Foundation

Source: MARKET WIRE

More News in this Category